Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled

Lucilla Poston1, Ruth Bell2, Helen Croker3

  • 1Division of Women's Health, King's College London, St Thomas' Hospital, London, UK.

Insights

A behavioral intervention for obese pregnant women did not reduce gestational diabetes or large-for-gestational-age infants. The UK Pregnancies Better Eating and Activity Trial (UPBEAT) found no significant differences in primary outcomes.

Area of Science:

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Public Health

Background:

  • Obesity in pregnancy is associated with adverse outcomes, including gestational diabetes and large-for-gestational-age infants.
  • Behavioral interventions targeting diet and physical activity are potential strategies to mitigate these risks.

Purpose of the Study:

  • To investigate the effectiveness of a complex behavioral intervention in reducing the incidence of gestational diabetes and large-for-gestational-age infants in obese pregnant women.

Main Methods:

  • The UK Pregnancies Better Eating and Activity Trial (UPBEAT) was a randomized controlled trial involving obese pregnant women (BMI ≥30 kg/m²).
  • Participants were randomized to a behavioral intervention (health trainer-led sessions on diet and physical activity) or standard antenatal care.
  • Primary outcomes included gestational diabetes diagnosis and delivery of large-for-gestational-age infants; intention-to-treat analysis was performed.

Main Results:

  • No significant difference was observed in the incidence of gestational diabetes between the intervention (25%) and standard care (26%) groups (RR 0.96, 95% CI 0.79-1.16).
  • The incidence of large-for-gestational-age infants also did not differ significantly between the groups (intervention 9% vs. standard care 8%; RR 1.15, 95% CI 0.83-1.59).
  • While primary outcomes were not met, the intervention group showed improvements in some maternal secondary outcomes, including reduced dietary glycaemic load and gestational weight gain.

Conclusions:

  • The studied behavioral intervention was not adequate to prevent gestational diabetes or reduce the incidence of large-for-gestational-age infants in obese pregnant women.
  • Despite the lack of effect on primary outcomes, the intervention demonstrated potential benefits in secondary maternal health indicators.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
343
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
394
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
288
Operant Conditioning Intervention01:24

Operant Conditioning Intervention

Operant conditioning serves as a foundational principle in therapeutic interventions aimed at modifying maladaptive behaviors. Central to this approach is the notion that behaviors, both adaptive and maladaptive, are learned through reinforcement. By analyzing the environmental factors that reinforce problematic behaviors, clinicians can design interventions to weaken these reinforcements and replace maladaptive behaviors with healthier alternatives.
In operant conditioning, behaviors that are...
657
Behavior Modification01:21

Behavior Modification

Behavioral approaches have often been criticized for ignoring mental processes and focusing solely on observable behavior. However, these approaches provide an optimistic perspective for individuals seeking to change their behaviors. Rather than concentrating on intrinsic personality traits, behavioral approaches suggest that even longstanding habits can be modified by changing the reward contingencies that maintain them.
A real-world application of operant conditioning principles is applied...
954